Menlo Park, CA, United States of America

Carrie Tomasi

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Gilead Sciences, Inc.. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Carrie Tomasi. Retrieved from https://idiyas.com/inventor/carrie-tomasi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Carrie Tomasi and Her Patent on Integrase Inhibitor Synthesis

Introduction

Carrie Tomasi is an inventor associated with Menlo Park, California, and Gilead Sciences, Inc. Her patent work concerns synthetic methods and intermediates for preparing compounds with integrase-inhibiting properties.

Latest Patents

Tomasi is named on one patent, titled “Process and Intermediates for Preparing Integrase Inhibitors.” The invention describes synthetic processes and intermediates that can be used to prepare 4-oxoquinolone compounds with useful integrase-inhibiting properties. Her listed portfolio includes 1 patent.

Career Highlights

Tomasi’s listed invention is connected to pharmaceutical chemistry and the preparation of compounds designed to inhibit integrase. The available information associates her work with Gilead Sciences, Inc.

Collaborations

The patent’s listed collaborators include Wenyi Fu and Dominika Pcion.

Conclusion

Carrie Tomasi’s patent contribution focuses on synthetic processes and intermediates for preparing 4-oxoquinolone integrase inhibitors, reflecting her association with pharmaceutical research at Gilead Sciences, Inc.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…